Navigation Links
EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries

VIENNA, Austria, June 4 /PRNewswire/ -- EUCODIS Bioscience, a company developing enzymes for the chemical, the pharmaceutical, and other industries, announced today that it has successfully launched its first commercial enzyme, a beta-lactamase. The product is manufactured by EUCODIS Bioscience and can be supplied in a GMP-compliant formulation. The Company will market its beta-lactamase to antibiotics manufacturers to improve quality control, to the diagnostics industry, and to research organizations. The Company estimates that its beta-lactamase has a market potential of up to EUR 5 million.

"The launch of a beta-lactamase for the antibiotics industry and other uses opens a new phase in the development of our organization," said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "The EUCODIS Bioscience team has demonstrated its capacity to cover the whole value-chain of an integrated enzyme supplier, from enzyme development, to manufacturing, and to marketing. This success adds momentum to our efforts to bring to market further products that we are currently developing. We will continue to provide our development expertise and our technology to industrial partners that want to increase their research and development efficiency."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visit

    Company contact EUCODIS Bioscience:

    Rudy Pandjaitan, PhD
    CEO EUCODIS Bioscience
    Brunner Strasse 59
    A-1230 Vienna

    Media contact EUCODIS Bioscience:

    Frank Butschbacher
    Investor Relations & Communications

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Signs Research Agreement With Genencor
2. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
3. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
4. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
5. Regado Biosciences Establishes Medical Advisory Board
6. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
8. Universite de Montreal and Validapro Biosciences Inc. have Signed an Agreement-in-Principle
10. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
11. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
Post Your Comments:
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
Breaking Biology Technology:
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):